DIA Global QPPV Forum

6-7 November 2024 |

Amsterdam, The Netherlands

WHAT ARE WE LOOKING FOR?

PRESENTATION ABSTRACTS* FOR QPPV TALKS

The QPPV Talks are designed to inspire participants through practical storytelling. Speakers will share their real-life challenges and offer practical solutions in brief talks, followed by a live Q&A session. The talks cover a range of themes that are of general interest, providing valuable insights and advice to attendees. Join us for a session packed with real-world examples and practical advice from seasoned Pharmacovigilance experts with relevance for the QPPVs. Give your experience a voice and share it with interested attendees who will be able to interact directly with you during the sessions and breaks.

We are particularly interested in speakers who can share practical experiences, best practices, lessons learned and case studies from a wide range of company types. Abstracts will be selected by DIA and the Programme Committee and their names will be published in the programme and on the DIA website.

* Please note that only scientific abstracts will be accepted for consideration, and we kindly request that all submissions refrain from including commercial bias.

Provide in your description answers to the following:

How is your abstract relevant for the DIA Global QPPV Forum? In a few short sentences, why should your abstract be accepted?

Maximum number of characters for Presentation abstracts:

Abstract title 125 Briefly describe the focus of the abstract and accurately reflect the content of the abstract. Keywords 100 Please provide one or more keywords associated with your abstract. These may be used for search purposes should your

abstract be selected as a concept.

Learning Objectives 300 Please provide a few bullet points on the objective of the abstract. Abstract Details 2000

QPPV TALKS FORMAT

The QPPV Talks follow a specific format, with brief and impactful presentations. In just **10 minutes** speakers will share their insights and practical advice on a variety of themes of general interest to QPPVs, providing attendees with valuable takeaways that they can apply in their own work. The interactive **10 minute Q&A session** that follows will allow participants to engage in meaningful dialogue with the speakers, making this session an inspiring and thought-provoking experience for all.

ABSTRACT WINNERS

The Programme Committee will carefully select **the most relevant abstracts** for in-person presentations at the upcoming conference in Amsterdam. As a selected speaker, you will receive complimentary conference registration, providing a unique chance to network with peers and gain valuable insights into the latest trends.

For other selected abstracts, we are offering the chance to present your projects/practical cases live in a free webinar to a wider audience. This will allow you to showcase your work and build interest ahead of the main event.

POTENTIAL TOPICS

You can share any case study you feel can be inspiring for other QPPVs:

• What challenge have you encountered (and hopefully solved) that you could share with your peers?

Some examples could be:

Is there a role for QPPVs in devices?

• Are you (also) responsible for medical devices? How have you integrated that (if at all) into your PV system for the medicinal products you are responsible for?

When and how to reach out to regulators?

• Do you pro-actively reach out to regulators (instead of waiting for an inspection)? On what topics? And what would you suggest as best approach?

QPPVs and regulatory authority portals

• What systems do you have in place to navigate and ensure appropriate registrations for EudraVigilance, XEVMPD, MHRA portal, IRIS portal, PharmNet portal etc.?

QPPV and PV regulatory intelligence

 How do you monitor (key) regulatory agencies websites for important information on products safety and pharmacovigilance system expectations?

DEADLINES

Submit Abstracts by Friday, 26 of April 2024

All abstracts have to be submitted online at http://www.diaglobal.org/get-involved/abstracts

Notification Date Submitters will be notified of the status of each abstract no later than the week ending 17 May 2024.

GET IN TOUCH

We are happy to help! If you have questions about abstract submission, please contact DIA Europe on +41 61 225 51 42 or email <u>EMEA.Meetings@diaglobal.org</u>